Mendus: Interview About New Trials and Clinical Landscapes
15 april, 07:15
15 april, 07:15
Redeye interviews Mendus' CEO Erik Manting. We talk about the recently started clinical programme in CML and how vididencel is positioned relative to TERN-701, which was acquired recently at a record-high valuation. We also discuss the expanded AML programme, including the DIVA study.
15 april, 07:15
Redeye interviews Mendus' CEO Erik Manting. We talk about the recently started clinical programme in CML and how vididencel is positioned relative to TERN-701, which was acquired recently at a record-high valuation. We also discuss the expanded AML programme, including the DIVA study.
Rapporter
Analys
Rapporter
Analys
1 DAG %
Senast
OMX Stockholm 30
0,00%
(13:27)
Ekobrott
Idag, 13:22
Günther Mårder släpps ur häktet
OMX Stockholm 30
1 DAG %
Senast
3 054,72